Article
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Oncology (Williston Park, N.Y.) - 12 Aug 2020
Darabi Sourat, Braxton David R, Eisenberg Burton L, Demeure Michael J
Abstract excerpt
Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.